Latest News- Gastrointestinal Stromal Tumors Therapeutics Market: Oral is expected to lead the Route Of Administration segment during 2025-2029

The Gastrointestinal Stromal Tumors Therapeutics Market is being driven by Growing geriatric population

The Gastrointestinal Stromal Tumors Therapeutics Market is expected to grow at a CAGR of 7.4% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 525 million. The gastrointestinal stromal tumors (GISTs) therapeutics market faces a significant challenge due to the disease's propensity to recur after surgical intervention. Adjuvant therapies are often required to address the residual tumor, and even post-complete removal, recurrence is a possibility. To combat this, the industry focuses on developing targeted therapies, such as tyrosine kinase inhibitors, and explores regenerative therapies, including gene therapy, for a potential cure. Research indicates that specific genes, like KIT and PDGFRA, contribute to GISTs' progression, necessitating ongoing research and innovation in this field. 

Get more information on Gastrointestinal Stromal Tumors Therapeutics Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Route Of Administration
  • Oral
  • Parenteral
• Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Therapy
  • Targeted therapy
  • Chemotherapy
  • Immunotherapy
  • Others
• Geography
  • North America
    • Canada
    • Mexico
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
  • Asia
    • China
    • India
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Growing geriatric population
• Growing adoption of GIST therapeutics
• Increasing awareness campaigns about GIST

However, the market also witnesses some limitations, which are as follows:

• High treatment costs of GIST
• Patent expiry of multiple GIST drugs
• Low prevalence of GIST disease

Benefits of Buying Global Gastrointestinal Stromal Tumors Therapeutics Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Gastrointestinal Stromal Tumors Therapeutics Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Gastrointestinal Stromal Tumors (GISTs) Therapeutics Market encompasses innovative treatments for various molecular subtypes, including those with kit and PDGFRA mutations. Car-T cell therapy and drug repurposing are emerging approaches. Multidisciplinary care, liquid biopsy, and understanding tumor microenvironment and drug resistance mechanisms are crucial. Clinical trials, including randomized controlled trials and observational studies, assess treatment efficacy and patient outcomes. Healthcare costs, insurance coverage, patient-reported outcomes, satisfaction, and adherence are essential considerations. Long-term follow-up, survival analysis using Kaplan-Meier curves, genetic counseling, and family history play significant roles in managing GISTs.

Market Research Overview

The gastrointestinal stromal tumors (GISTs) therapeutics market is a significant segment within the larger global pharmaceuticals market. This sector focuses on the development and production of targeted therapies, specifically tyrosine kinase inhibitors, such as imatinib mesylate and sunitinib malate. Key players in this market include manufacturers and providers of these specialized drugs. The growth of this market is driven by the increasing prevalence of GISTs, particularly in an aging population. By 2050, approximately one-quarter of the US and European populations are projected to be over 60 years old, increasing the demand for effective GIST treatments. Additionally, emerging therapies like checkpoint inhibitors are undergoing clinical trials to further expand treatment options for patients.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/